GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system by Hruz, Paul W et al.




GS-8374, a novel HIV protease inhibitor, does not
alter glucose homeostasis in cultured adipocytes or
in a healthy-rodent model system
Paul W. Hruz
Washington University School of Medicine in St. Louis
Qingyun Yan




Washington University School of Medicine in St. Louis
Lianhong Xu
Gilead Sciences
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Hruz, Paul W.; Yan, Qingyun; Tsai, Luong; Koster, Joseph; Xu, Lianhong; Cihlar, Tomas; and Callebaut, Christian, ,"GS-8374, a novel
HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system." Antimicrobial
Agents and Chemotherapy.55,4. 1377. (2011).
http://digitalcommons.wustl.edu/open_access_pubs/2338
Authors
Paul W. Hruz, Qingyun Yan, Luong Tsai, Joseph Koster, Lianhong Xu, Tomas Cihlar, and Christian Callebaut
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/2338
  Published Ahead of Print 18 January 2011. 
10.1128/AAC.01184-10. 
2011, 55(4):1377. DOI:Antimicrob. Agents Chemother. 
Lianhong Xu, Tomas Cihlar and Christian Callebaut
Paul W. Hruz, Qingyun Yan, Luong Tsai, Joseph Koster,
 
Model System
Cultured Adipocytes or in a Healthy-Rodent
Does Not Alter Glucose Homeostasis in 
GS-8374, a Novel HIV Protease Inhibitor,
http://aac.asm.org/content/55/4/1377




This article cites 23 articles, 8 of which can be accessed free at:
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 




arch 8, 2014 by W










arch 8, 2014 by W







ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2011, p. 1377–1382 Vol. 55, No. 4
0066-4804/11/$12.00 doi:10.1128/AAC.01184-10
Copyright © 2011, American Society for Microbiology. All Rights Reserved.
GS-8374, a Novel HIV Protease Inhibitor, Does Not Alter Glucose
Homeostasis in Cultured Adipocytes or in a
Healthy-Rodent Model System
Paul W. Hruz,1,2* Qingyun Yan,1 Luong Tsai,3 Joseph Koster,1 Lianhong Xu,3
Tomas Cihlar,3 and Christian Callebaut3*
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Adverse effects induced by HIV protease inhibitors (PIs) are a significant factor in limiting their clinical
success. PIs directly contribute to peripheral insulin resistance and alterations in lipid metabolism. GS-8374
is a novel PI with potent antiretroviral activity and a favorable resistance profile. Here we report on the
potential of GS-8374 to adversely affect glucose and lipid homeostasis. Acute effects of GS-8374 and control PIs
on glucose uptake and lipid accumulation were assessed in vitro in mouse OP9 and primary human adipocytes,
respectively. GS-8374 and atazanavir showed no effect on insulin-stimulated deoxyglucose uptake, whereas
ritonavir and lopinavir caused significant reductions. Similarly, in vitro lipid accumulation was not signifi-
cantly affected in adipocytes treated with either GS-8374 or atazanavir. In euglycemic-hyperinsulinemic clamp
experiments performed in rats during acute infusion of therapeutic levels of PIs, sustained serum GS-8374
levels of 8 Mhad no effect on peripheral glucose disposal (similar to the findings for atazanavir). Comparable
serum levels of lopinavir and ritonavir produced acute 19% and 53% reductions in in vivo glucose disposal,
respectively. In conclusion, similar to atazanavir, but unlike ritonavir and lopinavir, GS-8374 neither affects
insulin-stimulated glucose uptake in adipocytes in culture nor acutely alters peripheral glucose disposal in a
rodent model system. These results dissociate the antiretroviral activity of GS-8374 from adverse effects on
insulin sensitivity observed with some of the first-generation PIs and provide further support for the use of
these experimental systems in the preclinical evaluation of novel PIs.
With the development and clinical introduction of HIV pro-
tease inhibitors (PIs) over a decade ago, HIV infection has
transitioned from a once fatal condition to a chronic, treatable
disease. While HIV integrase and entry inhibitors have re-
cently been added to antiretroviral therapeutic arsenals, PIs
together with reverse transcriptase inhibitors remain a corner-
stone of many highly active antiretroviral treatment (HAART)
regimens. Despite the dramatic reduction in HIV-associated
morbidity and mortality observed in the HAART era (20),
enthusiasm for some of the currently available therapies is
partly tempered by their propensity to induce adverse meta-
bolic effects (7, 23) and/or by the development of viral resis-
tance over time (15). Thus, there is a continuing need for the
development of safer and more effective antiretroviral agents.
The complexity of HAART regimens, together with the con-
founding effects of disease-related comorbidities, has chal-
lenged efforts to determine the association of individual drugs
with the various adverse effects observed in treated HIV-in-
fected patients. However, significant progress has been made
in understanding the acute effects of PIs on insulin sensitivity
through both in vitro and in vivo studies. The identification of
the insulin-responsive facilitative glucose transporter GLUT4
as a direct molecular target for acute effects of many of the
first-generation PIs (17) has provided insight into the specific
structural features of these antivirals that mediate this adverse
effect (8). In addition to direct inhibition of GLUT4, it has
been proposed that PIs may affect insulin sensitivity via mod-
ulating the insulin signaling pathways, including IRS-1 and -2
(24) and AKT (1). In contrast to the direct effects on GLUT4,
insulin signaling alterations have usually been observed follow-
ing chronic drug exposure. The relevance of the in vitro studies
to acute changes in whole-body glucose disposal has been
established by studying the acute effects of PIs in healthy HIV-
negative volunteers (12–14). These effects directly correlate
with the ability of PIs to influence peripheral glucose disposal
under euglycemic-hyperinsulinemic clamp conditions in a
healthy rodent model system (25). In this model, indinavir,
ritonavir, and lopinavir have all been shown to acutely reduce
peripheral glucose disposal. In contrast, atazanavir, which does
not adversely alter GLUT4 activity in vitro (25), does not ap-
pear to acutely induce insulin resistance in the rodent model or
in humans (18, 19). The use of atazanavir, however, is limited
primarily to PI-naïve patients due to substantial cross-resis-
tance with multiple other PIs (5).
Here we report on an in vitro and in vivo assessment of the
ability of a novel PI, GS-8374, to affect glucose disposal and
lipid metabolism. GS-8374 is a synthetic, peptidomimetic mol-
ecule containing a unique diethylphosphonate motif (Fig. 1).
In a separate virologic profiling, we have shown that GS-8374
is a potent and selective PI and that the phosphonate moiety
* Corresponding author. Mailing address for Paul W. Hruz: Wash-
ington University School of Medicine, 660 S. Euclid Ave., Campus Box
8208, St. Louis, MO 63110. Phone: (314) 286-2797. Fax: (314) 286-
2892. E-mail: hruz_p@kids.wustl.edu. Mailing address for Christian
Callebaut: Gilead Sciences, 333 Lakeside Dr., Foster City, CA 94404.
Phone: (650) 522-6362. Fax: (650) 522-5143. E-mail: christian
.callebaut@gilead.com.
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favorably affects its resistance profile (2, 3). In the present
study, we have investigated the effects of GS-8374 on cultured
differentiated adipocytes in terms of both lipid accumulation
and insulin-stimulated glucose uptake in comparison to the
effects of other PIs frequently used in the clinic. We have also
studied the acute effects of GS-8374 and selected control PIs
on peripheral insulin sensitivity in a healthy rodent model
system.
MATERIALS AND METHODS
Materials. 2-Deoxy-1-[3H]glucose was purchased from Sigma (St. Louis, MO).
Reference standards for lopinavir, ritonavir, and atazanavir were obtained from
the U.S. National Institutes of Health (NIH) AIDS Reference and Reagents
Program (Germantown, MD). GS-8374 was synthesized at Gilead Sciences (Fos-
ter City, CA). PIs used in the in vitro studies have been isolated from their
commercial formulations. Insulin (Humulin) was purchased from Eli Lilly (In-
dianapolis, IN). Primary human adipocytes and AdipoRed reagent were ob-
tained from Cambrex (East Rutherford, NJ). OP9 stromal cells were obtained
from ATCC (Manassas, VA). Male Wistar rats (weight, 125 to 150 g) were
purchased from Charles River (Wilmington, MA). MicroRenathane tubing for
venous catheters was obtained from Braintree Scientific (Braintree, MA). PE-50
tubing for arterial catheters was obtained from Becton Dickinson (Franklin
Lakes, NJ). Blood glucose levels were determined using a Glucometer Elite XL
device (Bayer, Tarrytown, NY). The assay kit for rat insulin determinations was
purchased from Linco (St. Charles, MO).
Lipid accumulation in primary human adipocytes. Human preadipocytes iso-
lated from subcutaneous adipose tissue (Cambrex) were grown in a preadipocyte
growth medium (PGM; PT 800; Cambrex) supplemented with 10% fetal bovine
serum (FBS) for a maximum of two passages, according to the vendor’s protocol.
Preadipocytes were seeded in PGM into 96-well plates at a density of 10,000 cells
per well. Cell differentiation was induced 24 h later by switching the cells into
differentiation medium (PGM supplemented with 10 g/ml insulin, 1 M dexa-
methasone, 200 M indomethacin, 500 M isobutyl-methylxanthine). Drugs to
be tested were added at the same time. The cells were maintained in the presence
of drugs for 8 days, with the drug-containing medium being replaced after 4 days.
At the end of the incubation period, the cytotoxicity of the drugs used was
evaluated by visual inspection of the cells under a light microscope. No changes
in cell morphology or density were observed for any of the tested concentrations.
The cells were then washed with phosphate-buffered saline (PBS), and intracel-
lular lipid accumulation was measured using Nile Red dye, specific for fluores-
cent staining of lipids (AdipoRed; Cambrex). After 10 min, fluorescence (exci-
tation at 485 nm, emission at 572 nm) was measured on a fluorescence plate
reader, and the effective concentration of each drug reducing the fluorescence
signal from Nile Red by 50% (EC50) was calculated (100% and 0% were defined
from the fluorescence signals in vehicle-treated cells and undifferentiated cells,
respectively).
Glucose uptake in cultured mouse adipocytes. Mouse OP9 preadipocytes
(catalog no. CRL 2749; ATCC) were maintained in basal medium (BM; minimal
essential alpha medium supplemented with 1.5 g/liter sodium bicarbonate, 20%
FBS, and 1% antibiotic solution). OP9 cells were passaged twice a week and kept
below 70% confluence. For testing of PIs, the cells were seeded in basal medium
into 24-well plates at a density of 70,000 cells per well. Cell differentiation was
induced 24 h later by switching the cells into a differentiation medium (Knock-
Out SR; Invitrogen) supplemented with 5 ng/ml of bone morphogenic protein-4
(BMP-4; R&D Systems, Minneapolis, MN). After 4 days, the differentiating cells
were switched back to regular growth medium and incubated for an additional 3
days, at which point the degree of cell differentiation was visually assessed by the
formation of lipid droplets in the cytoplasm. These conditions were found to
provide the lowest background uptake and least variability, thus being optimal
for the detection of specific glucose uptake upon insulin stimulation. At the time
of insulin response testing, the medium was removed; cells were washed and
exposed for 60 min to 10 M tested drugs in a Krebs Ringer HEPES buffer (121
mM NaCl, 4.9 mM KCl, 1.2 mM MgSO4, 0.33 mM CaCl2, 12 mM HEPES) with
or without 1 M insulin. Cells were then exposed to 2-deoxy-1-[3H]glucose for 10
min, washed three times with ice-cold PBS, and lysed in PBS with 0.3% Triton
X-100. Samples were analyzed by liquid scintillation counting. Inhibition of
insulin-stimulated glucose uptake was calculated as a percentage of the differ-
ence between the basal and insulin-stimulated deoxy-D-glucose uptake relative to
that for the untreated control.
Animal procedures. All animal procedures were approved by the Animal
Studies Committee at Washington University School of Medicine. Male Wistar
rats were housed in the animal facility at Washington University and maintained
in a controlled room with a 12-h light and 12-h dark cycle. The animals were
supplied with a standard rat chow diet and water ad libitum. Catheters were
inserted into the left internal carotid artery and right jugular vein while the rats
were under methohexital anesthesia as previously described (9). Rats were al-
lowed to recover from the stress of surgery at least 5 days before experiments
were performed. All animals weighed between 205 and 220 g at the time that
experiments were performed. Rats were fasted overnight before each experi-
ment.
Drug preparation and determination of plasma PI levels. Stock solutions of
ritonavir, atazanavir, and GS-8374 were prepared in 50% ethanol–50% normal
saline. Lopinavir stock solutions were prepared in 50% polyethylene glycol.
Serum PI levels were determined by the high-performance liquid chromatogra-
phy (HPLC) method of Foisy and Sommadossi (6) using a Waters 626 HPLC
system with a Microsorb C8 column. Samples were run in 50 l serum. Standard
curves were generated by adding serially diluted PIs directly to control rat serum.
Euglycemic-hyperinsulinemic clamp experiments. Catheters were flushed with
normal saline, and heparin (40 units/kg) was administered to maintain catheter
patency. After determination of fasting blood glucose levels, a constant infusion
FIG. 1. Structures of GS-8374, a novel HIV-1 protease inhibitor containing a diethylphosphonate motif, and comparative PIs used in the
glucose and lipid metabolism studies.




arch 8, 2014 by W







of the tested PIs or vehicle alone was started through the venous catheter at a
rate of 10 l/min using a Harvard 11 apparatus pump and was continued for the
duration of the clamp experiment. The total amount of ethanol or polyethylene
glycol infused was normalized to 5 l/kg of body weight/min and 2.8 l/kg/min,
respectively. After 30 min of drug infusion, insulin (10 mU/kg/min) in normal
saline containing 0.3% bovine serum albumin (BSA) was infused through the ve-
nous catheter. At 10-min intervals, 500 l of blood was removed from the
arterial catheter into a syringe. Blood (5 l) was then sampled directly from the
catheter to determine blood glucose levels. The dead-space blood was then
reinfused into the animal. Next, dextrose (50%) was infused through the venous
catheter at a rate sufficient to maintain a plasma glucose level of 100 to 110
mg/dl. Insulin sensitivity was determined by the average infusion rate during the
final 30 min of each 90-min clamp experiment.
Statistical analysis. Data are presented as means  standard deviations.
Statistical differences among groups in the in vivo studies were tested using
analysis of variance (ANOVA) with the post hoc Bonferroni test. Differences
were assumed to be significant in each case if P was 0.05, unless indicated
otherwise; nonsignificant differences are not indicated.
RESULTS
In vitro effect of PIs on lipid accumulation in adipocytes.
Previously, we have demonstrated that the effect of PIs on adi-
pocyte function in vitro accurately predicts their metabolic actions
in vivo (25). To determine the effect of GS-8374 on lipid homeo-
stasis, primary human adipocytes were cultured for 8 days in the
presence or absence of selected PIs, after which lipid accumula-
tion was assessed (see Materials and Methods). As shown in
Table 1, GS-8374, along with atazanavir, amprenavir, indinavir,
and darunavir, had a negligible effect on lipid accumulation com-
pared to that for the vehicle-treated control, with the predicted
EC50 being greater than 30 M, a value significantly higher than
the therapeutic concentrations of the drugs (21). Conversely, nel-
finavir, saquinavir, lopinavir, and ritonavir all significantly inhib-
ited lipid accumulation, with calculated EC50s being 8 to 17 M,
representing levels approaching their maximum plasma therapeu-
tic concentration range.
In vitro effect of PIs on insulin-stimulated glucose uptake.
Next, the effects of GS-8374 and selected PIs on glucose up-
take were assessed in cultured mouse OP9 differentiated adi-
pocytes. In general, there was a trend for a correlation between
the effects of the respective PI on lipid accumulation and
glucose uptake (Table 2). Those PIs that had negligible effects
on lipid accumulation in primary human adipocytes (GS-8374,
darunavir, atazanavir, and amprenavir; EC50s  30 M) also
did not appreciably block glucose uptake in the OP9 adi-
pocytes (8.1% inhibition at 10 M versus that for the vehicle-
treated control). Notably, indinavir showed no effect on lipid
accumulation but inhibited the glucose uptake, thus being an
exception to this trend. However, it should be noted that the
effect of indinavir on the insulin-stimulated glucose uptake was
somewhat variable, which is in contrast to the reproducible
results obtained with all the other PIs. Conversely, PIs such as
ritonavir, lopinavir, and saquinavir that showed a measurable
inhibition of lipid accumulation (EC50s 20 M) also blocked
glucose uptake to a greater extent. These data suggest that for
some PIs the effect on glucose uptake may in part contribute to
reduced lipid accumulation. Notably, GS-8374 had no discern-
ible effect on glucose uptake relative to that for the control, a
result similar to the results for atazanavir, amprenavir, and
darunavir. On the basis of our previous biochemical studies of
PI action, we conclude that the lack of an effect of GS-8374 on
acute glucose uptake reflects its inability to directly target and
block the insulin-sensitive GLUT4 transporters in the cultured
adipocytes.
Acute in vivo effects of PIs on peripheral glucose disposal.
The effects of PIs on glucose uptake in vitro should also be
evident in vivo and reflected by a concomitant change in pe-
ripheral insulin sensitivity. To assess the effect of GS-8374 on
glucose disposal, euglycemic-hyperinsulinemic clamps (4) were
performed on healthy, PI-naïve rats. In these experiments,
insulin (10 mU/kg/min) and PIs were administered by constant
intravenous infusion in order to maintain serum PI levels of 8
to 10 M. This is within the therapeutic range for peak serum
drug levels achieved in treated human patients for currently
marketed PIs (21). Together with constant insulin administra-
tion, glucose was continuously infused at a variable rate in
order to maintain the serum glucose level at 110 mg/dl (Table
3). Under steady-state conditions, peripheral insulin sensitivity
directly correlates with the rate of glucose infusion necessary to
maintain the target serum glucose level. As a negative control,
rat clamps were performed using atazanavir, as this PI has
previously been shown not to affect peripheral insulin sensitiv-
ity in this rodent model system (25). Conversely, ritonavir,
which does alter insulin sensitivity, was used as a positive con-
trol. Serum insulin levels achieved during the euglycemic
clamp experiments, as well as serum glucose levels, were not
significantly different from those in vehicle-treated animals
(Table 3). As shown in Fig. 2, the rates of glucose infusion in
GS-8374-treated rats over the 90-min experiment approxi-
mated those observed for vehicle- or atazanavir-treated rats.
Conversely, the infusion rates were significantly lower in the
TABLE 1. Effects of GS-8374 and marketed PIs on lipid accumulation
in primary human adipocytes in vitro









a Data shown represent means  standard deviations from at least four inde-
pendent experiments. DMSO was used as a vehicle control; no effect on lipid
accumulation was observed in the presence of DMSO.
TABLE 2. Effects of GS-8374 and marketed PIs on insulin-stimulated
glucose uptake in mouse adipocytes in vitro
Protease inhibitor % inhibition of glucoseuptake at 10 Ma
GS-8374 .........................................................................0.1  0.1
Darunavir ......................................................................0.7  1.2
Lopinavir ....................................................................... 44.0 1.7
Atazanavir ..................................................................... 0.3 0.6
Ritonavir........................................................................ 60.7 1.2
Amprenavir ................................................................... 8.1 1.6
Indinavir ........................................................................ 14.0 12.5
Nelfinavir....................................................................... 28.4 8.2
a Data shown represent means  standard deviations from three independent
experiments. DMSO was used as a vehicle control; no effect on glucose uptake
was observed in the presence of DMSO.
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ritonavir- and lopinavir-treated rats, consistent with a drug-
induced reduction in peripheral insulin sensitivity. The average
glucose disposal rates (Rd; mg/kg/min) under steady-state con-
ditions (i.e., during the final 30 min of the clamp) are summa-
rized in Table 3. Importantly, the average serum drug levels
were similar for all three drugs (Table 3). In summary, the
clamp data corroborate the in vitro data and indicate that
GS-8374 does not alter in vivo glucose disposal in peripheral
tissues.
DISCUSSION
The long-term successful use of PIs as a part of increasingly
effective antiretroviral combination therapy requires potent
TABLE 3. Comparison of glucose disposal in rats infused with GS-8374 or control PIs








rate (% of control)
Vehicle 105.3 7.4 4.62  1.03 NA 47.1  1.6 100
GS-8374 105.6 1.3 4.07  2.19 7.7  0.4 47.0  0.2 99.7
Atazanavir 104.4 3.3 5.21  0.69 9.4  1.5 46.6  0.9 99.1
Lopinavir 103.3 1.7 4.12  2.40 10.9  1.1 38.0  0.6c 80.8
Ritonavir 109.2 1.6 3.65  0.87 8.7  0.4 22.3  1.6c 47.4
a All values represent the means  standard deviations from three and four different vehicle- and drug-treated animals, respectively. NA, not applicable.
b Rate of glucose disposal (mg/kg/min) was averaged from measurements from the last 30 min of each experiment.
c Statistically significant difference from vehicle-treated animals, as determined by ANOVA with the Bonferonni post hoc test (P  0.01).
FIG. 2. Acute effects of GS-8374 and other PIs on peripheral insulin sensitivity. Catheters were inserted into the carotid arteries and jugular
veins of 200- to 300-g male Wistar rats at least 4 days prior to experiments. Euglycemic-hyperinsulinemic clamps were performed using 40
mU/kg/min regular human insulin. The rate of infusion of 50% dextrose was adjusted to maintain plasma glucose levels at 110 mg/dl (Table 2).
Insulin sensitivity was determined by the average rate of glucose infusion (Rd) over the final 30 min (steady-state phase) of each 2-hour experiment
(gray-shaded region). Data represent means standard deviations, with n 3 and 4 for vehicle and each of the drug-treated animals, respectively.
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drugs with favorable viral resistance and metabolic profiles. In
virological studies presented in parallel with this report, we
have characterized the unique viral resistance properties of a
novel, potent PI, GS-8374 (2). In the present study, we dem-
onstrate that GS-8374 does not adversely affect glucose or lipid
metabolism either in vitro or in vivo. This conclusion is based
on several lines of evidence. First, treatment of human primary
adipocytes for 8 days with GS-8374 or atazanavir at concen-
trations up to 30 M showed no effect on normal lipid accu-
mulation. Under the same conditions, ritonavir and lopinavir
affected lipid accumulation with EC50s of 17 and 16 M, re-
spectively. Second, acute treatment of differentiated OP9
mouse adipocytes with GS-8374 or atazanavir showed no effect
on insulin-stimulated 2-deoxyglucose uptake, whereas ritonavir
and lopinavir caused 60 and 44% inhibition, respectively, un-
der the same assay conditions. Finally, in a rat model system,
sustained serum levels of GS-8374 reaching approximately 8
M had no acute effect on peripheral glucose disposal com-
pared to the effect of vehicle or atazanavir treatment. Consis-
tent with previous studies (25), comparable serum levels of
ritonavir or lopinavir produced an acute reduction of glucose
disposal. We hypothesize that, similar to atazanavir (5, 25), the
lack of acute effects of GS-8374 on insulin sensitivity in vivo
reflects its inability to directly target and block insulin-sensitive
GLUT4 in skeletal muscle and fat tissues. On the basis of the
antiviral potency, favorable resistance profile, and moderate
serum protein binding (2), we expect that GS-8374 serum lev-
els lower than those achieved in the in vivo insulin sensitivity
study would be sufficient for a potent clinical antiviral effect in
both treatment-naïve and PI-experienced patients.
Our earlier demonstration that aromatic peptides mimicking
the core peptidic structure found in most PIs also block glucose
uptake suggested that the aromatic peptide backbone is im-
portant for the ability of PIs to interact with GLUT4 (8).
Furthermore, the demonstration that the dihydropyrone-based
PI tipranavir does not acutely influence peripheral glucose
disposal further supported the importance of the peptidomi-
metic structure in mediating the inhibition of GLUT4 activity
(10). PIs such as indinavir and ritonavir have been shown to
directly affect GLUT4 activity through noncompetitive inhibi-
tion (16, 17). In contrast, atazanavir has been shown to be
devoid of direct inhibitory effects on GLUT4 transport activity,
possibly due to steric interference preventing GLUT4 binding
because of the presence of a pyridine ring and/or a reduced
overall hydrophobicity of atazanavir compared to that of most
of the first-generation PIs. Interestingly, our data demon-
strated that darunavir, despite the presence of the signature
aromatic peptidomimetic motif in its structure (11), does not
appear to adversely affect the metabolic status of differentiated
adipocytes. This indicates that more complex interactions are
likely to affect the binding of peptidomimetic PIs to GLUT4.
Importantly, the unique diethylphosphonate moiety present
within GS-8374, which itself is a close structural analog of
darunavir, does not appear to increase its interaction with
GLUT4 relative to that of darunavir.
While the development of potent PIs has been strongly in-
fluenced by rational structure-based design (22), the binding
site of PIs to GLUT4 remains to be established, and an X-ray
crystal structure for this transporter is not yet available. Thus,
molecular modeling similar to that used in addressing the
problem of viral resistance has not been possible for predicting
the effects of PIs on glucose metabolism and homeostasis. As
the development of newer generations of PIs and other anti-
retroviral agents continues, the use of effective strategies to
screen for potential drug-related toxicities will become increas-
ingly important.
In summary, the current studies suggest that GS-8374 has a
low potential for metabolic adverse effects compared to the
potentials of some other PIs and confirm that these effects are
not inherently linked to the antiretroviral activity of PIs. Im-
portantly, these data provide further support for the use of in
vitro cultured adipocyte and in vivo rodent clamp systems in the
preclinical evaluation of the safety of novel PIs. Further pro-
gression of GS-8374 development should allow the first pro-
spective analysis and confirmation of this approach.
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